{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:26:08Z","timestamp":1788639968724,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11095-022-03425-5","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T23:29:18Z","timestamp":1667518158000},"page":"187-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Differences in Pharmacokinetic\/Pharmacodynamic Parameters of Tedizolid Against VRE and MRSA"],"prefix":"10.1007","volume":"40","author":[{"given":"Xiaoxi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-0670","authenticated-orcid":false,"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"3425_CR1","doi-asserted-by":"crossref","unstructured":"Shrestha S, Kharel S, Homagain S, Aryal R, Mishra SK. Prevalence of vancomycin\u2010resistant enterococci in Asia\u2014A systematic review and meta-analysis. J Clin Pharm Ther. 2021;46:1226\u201337.\u00a0https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.13383.","DOI":"10.1111\/jcpt.13383"},{"key":"3425_CR2","unstructured":"Lebreton F, Willems RJL, Gilmore MS, et al. Enterococcus diversity, origins in nature, and gut colonization; 2014.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK190427\/. Boston: Massachusetts Eye and Ear Infirmary."},{"key":"3425_CR3","doi-asserted-by":"crossref","unstructured":"Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000;13:686\u2013707.\u00a0\u00a0http:\/\/cmr.asm.org\/cgi\/doi\/10.1128\/CMR.13.4.686-707.2000.","DOI":"10.1128\/CMR.13.4.686"},{"key":"3425_CR4","doi-asserted-by":"publisher","unstructured":"Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: Colonization, infection, detection, and treatment. Mayo Clin Proc. 2006;81:529\u201336. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611619010. https:\/\/doi.org\/10.4065\/81.4.529","DOI":"10.4065\/81.4.529"},{"key":"3425_CR5","doi-asserted-by":"crossref","unstructured":"Sandison T, De Anda C, Fang E, Das AF, Prokocimer P. Clinical Response of tedizolid versus linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials. Antimicrob Agents Chemother. 2017;61.\u00a0https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02687-16.","DOI":"10.1128\/AAC.02687-16"},{"key":"3425_CR6","doi-asserted-by":"crossref","unstructured":"Lodise TP, Fang E, Minassian SL, Prokocimer PG. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: Findings from the Phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother. 2014;58:7198\u2013204.\u00a0https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03509-14.","DOI":"10.1128\/AAC.03509-14"},{"key":"3425_CR7","doi-asserted-by":"publisher","unstructured":"Wang Y, Lv Y, Cai J, Schwarz S, Cui L, Hu Z, et al. A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. J Antimicrob Chemother. 2015;70:2182\u201390. https:\/\/academic.oup.com\/jac\/article\/70\/8\/2182\/812642. https:\/\/doi.org\/10.1093\/jac\/dkv116","DOI":"10.1093\/jac\/dkv116"},{"key":"3425_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.diagmicrobio.2014.08.011","volume":"81","author":"DF Sahm","year":"2015","unstructured":"Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, et al. Results of the surveillance of tedizolid activity and resistance program: In vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis. 2015;81:112\u20138. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.08.011.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3425_CR9","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1128\/AAC.00502-11","volume":"55","author":"GL Drusano","year":"2011","unstructured":"Drusano GL, Liu W, Kulawy R, Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother. 2011;55:5300\u20135. https:\/\/doi.org\/10.1128\/AAC.00502-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"3425_CR10","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014Tenth edition: M07-A10. Wayne, PA: NCCLS; 2015"},{"key":"3425_CR11","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for antimicrobial Susceptibility Testing\u2014Twenty-seventh edition: M100. Wayne, PA: NCCLS; 2017"},{"key":"3425_CR12","unstructured":"Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents;approved guideline: M26-A. Wayne, PA: NCCLS; 1999"},{"key":"3425_CR13","doi-asserted-by":"publisher","unstructured":"Yokoyama Y, Matsumoto K, Ikawa K, Watanabe E, Shigemi A, Umezaki Y, et al. Pharmacokinetic\/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models. Int J Antimicrob Agents. 2014;43:547\u201352. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857914000831. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.02.012","DOI":"10.1016\/j.ijantimicag.2014.02.012"},{"key":"3425_CR14","doi-asserted-by":"crossref","unstructured":"Zuluaga AF, Salazar BE, Rodriguez CA, Zapata AX, Agudelo M, Vesga O. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: Characterization and applicability to diverse experimental models of infectious diseases. BMC Infect Dis. 2006;6:55.\u00a0\u00a0https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-6-55.","DOI":"10.1186\/1471-2334-6-55"},{"issue":"8","key":"3425_CR15","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1124\/dmd.113.056697","volume":"42","author":"V Ong","year":"2014","unstructured":"Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014;42(8):1275\u201384.","journal-title":"Drug Metab Dispos"},{"key":"3425_CR16","doi-asserted-by":"crossref","unstructured":"Craig WA. The postantibiotic effect. Clin Microbiol Newsl. 1991;13:121\u20134.\u00a0https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/019643999190030Y.","DOI":"10.1016\/0196-4399(91)90030-Y"},{"key":"3425_CR17","doi-asserted-by":"crossref","unstructured":"Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of faropenem demonstrated by studies of 1997. p. 415\u20138","DOI":"10.1093\/jac\/39.3.415"},{"key":"3425_CR18","doi-asserted-by":"crossref","unstructured":"Abdelhady W, Mishra NN. Comparative Efficacies of linezolid vs. tedizolid in an Experimental Murine Model of Vancomycin-Resistant Enterococcal (VRE) bacteremia. Front Med (Lausanne). 2019;6. https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00031\/full:31.","DOI":"10.3389\/fmed.2019.00031"},{"key":"3425_CR19","doi-asserted-by":"crossref","unstructured":"Wang S, Liu H, Mao J, Peng Y, Yan Y, Li Y, et al. Pharmacodynamics of linezolid plus fosfomycin against vancomycin\u2013resistant Enterococcus faecium in a hollow fiber infection model. Front Microbiol. 2021;12. https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.779885\/full:779885.","DOI":"10.3389\/fmicb.2021.779885"},{"key":"3425_CR20","doi-asserted-by":"crossref","unstructured":"McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother. 2009;63:1191\u20139. https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkp126.","DOI":"10.1093\/jac\/dkp126"},{"key":"3425_CR21","doi-asserted-by":"crossref","unstructured":"Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother. 1996;38:589\u201397. https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/38.4.589.","DOI":"10.1093\/jac\/38.4.589"},{"key":"3425_CR22","doi-asserted-by":"crossref","unstructured":"Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42;Suppl 1(Supplement_1):S35\u20139. http:\/\/academic.oup.com\/cid\/article\/42\/Supplement_1\/S35\/275535\/The-Pharmacokinetic-and-Pharmacodynamic-Properties.","DOI":"10.1086\/491712"},{"key":"3425_CR23","doi-asserted-by":"crossref","unstructured":"Takemura W, Tashiro S, Hayashi M, Igarashi Y, Liu X, Mizukami Y, et al. Cefmetazole as an alternative to carbapenems against extended-spectrum beta-lactamase-producing Escherichia coli infections based on in vitro and in vivo pharmacokinetics\/pharmacodynamics experiments. Pharm Res. 2021;38:1839\u201346. https:\/\/link.springer.com\/10.1007\/s11095-021-03140-7.","DOI":"10.1007\/s11095-021-03140-7"},{"key":"3425_CR24","doi-asserted-by":"crossref","unstructured":"Fuentes F, Izquierdo J, Mart\u00edn MM, Gomez-Lus ML, Prieto J. Postantibiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli. Vol. 42, Antimicrobial Agents and Chemotherapy. 1998. p. 414\u20138.","DOI":"10.1128\/AAC.42.2.414"},{"key":"3425_CR25","doi-asserted-by":"crossref","unstructured":"Li RC, Zhu ZY. The integration of four major determinants of Antibiotic Action: Bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics. J Chemother. 2002;14:579\u201383. http:\/\/www.tandfonline.com\/doi\/full\/10.1179\/joc.2002.14.6.579.","DOI":"10.1179\/joc.2002.14.6.579"},{"key":"3425_CR26","doi-asserted-by":"publisher","unstructured":"Carvalhaes CG, Sader HS, Flamm RK, Streit JM, Mendes RE. Assessment of tedizolid in vitro activity and resistance mechanisms against a collection of Enterococcus spp. causing invasive infections, including isolates requiring an optimized dosing strategy for daptomycin from U.S. and European Medical Centers, 2016 to 2018. Antimicrob Agents Chemother. 2020;64:2016\u20138. https:\/\/doi.org\/10.1128\/AAC.00175-20","DOI":"10.1128\/AAC.00175-20"},{"key":"3425_CR27","doi-asserted-by":"crossref","unstructured":"Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, et al. Antimicrobial resistance: Pharmacokinetics\u2010pharmacodynamics of Antimicrobial Therapy: It\u2019s not just for mice anymore. Clin Infect Dis. 2007;44:79\u201386. https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/ 10.1086\/510079.","DOI":"10.1086\/510079"},{"key":"3425_CR28","doi-asserted-by":"publisher","unstructured":"Chen R, Shen K, Chang X, Tanaka T, Li L, Hu P. Pharmacokinetics and safety of tedizolid after single and multiple intravenous\/oral sequential administrations in healthy Chinese subjects. Clin Ther. 2016;38:1869\u201379. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816304295. https:\/\/doi.org\/10.1016\/j.clinthera.2016.06.014","DOI":"10.1016\/j.clinthera.2016.06.014"},{"key":"3425_CR29","doi-asserted-by":"publisher","unstructured":"Kim Y, Kim A, Lee S, Choi SH, Lee DY, Song JS, et al. Pharmacokinetics, safety, and tolerability of tedizolid phosphate after single-dose administration in healthy Korean male subjects. Clin Ther. 2017;39:1849\u201357. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817308731. https:\/\/doi.org\/10.1016\/j.clinthera.2017.08.002","DOI":"10.1016\/j.clinthera.2017.08.002"},{"key":"3425_CR30","doi-asserted-by":"publisher","unstructured":"Patterson JE, Sweeney AH, Simms M, Carley N, Mangi R, Sabetta J, et al. An analysis of 110 enterococcal infections epidemiology, antibiotic susceptibility, and outcome. Med (Baltim). 1995;74:191\u2013200. http:\/\/journals.lww.com\/00005792-199507000-00003. https:\/\/doi.org\/10.1097\/00005792-199507000-00003","DOI":"10.1097\/00005792-199507000-00003"},{"key":"3425_CR31","doi-asserted-by":"publisher","unstructured":"Xiao J, Gill C, Liang L, Liu J, Wu J, Tan CM, et al. Use of translational PKPD infection models to understand impact of neutropenia on efficacy of tedizolid phosphate. Open Forum Infect Dis. 2017;4(suppl_1):S292\u2013S292. https:\/\/doi.org\/10.1093\/ofid\/ofx163.667","DOI":"10.1093\/ofid\/ofx163.667"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03425-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-022-03425-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03425-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T15:25:41Z","timestamp":1676301941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-022-03425-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3425"],"URL":"https:\/\/doi.org\/10.1007\/s11095-022-03425-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]},"assertion":[{"value":"24 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}